In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Previews (5/07)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: In Inflammation, the Indication's the Thing, features profiles of Anthera Pharmaceuticals, Logical Therapeutics, Opsona Therapeutics and VLST Corp.. Plus these Start-Ups Across Health Care: Biodesy, Magenta Medical and NuLens.

You may also be interested in...

Magenta Medical Corp.

Magenta Medical is developing a device that provides hemostasis during minimally-invasive off pump coronary artery bypass graft surgery, without the use of an aortic clamp. Its founder is Dartmouth interventional cardiologist-entrepreneur Aaron Kaplan, whose previous start-ups include LocalMed and Perclose.

Anthera Pharmaceuticals Inc.

The founder of Peninsula Pharmaceuticals brought investors huge multiples fast by exploiting trans-Pacific dealmaking opportunities. He's now following the same route with Anthera Pharmaceuticals in hopes of repeating his earlier success.

NuLens Ltd.

Today, most of the accommodating and multifocal IOLs that address presbyopia share one thing in common: they are placed, as are the standard lenses used in routine cataract procedures, inside the capsular bag, a thin membrane surrounding the eye's natural lens. It's becoming increasingly apparent that over time, the capsular bag undergoes changes that compromise visual results. NuLens came up with the idea of not using the capsular bag as the housing for the accommodating lens.

Related Content

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts